Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Shares Outstanding (Diluted Average) (2016 - 2025)

Cumberland Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 16 years, with the latest figure at $14.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 5.65% year-over-year to $14.9 million; the TTM value through Dec 2025 reached $14.9 million, up 5.65%, while the annual FY2025 figure was $14.9 million, 5.65% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $14.9 million at Cumberland Pharmaceuticals, down from $15.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $15.3 million in Q2 2025 and bottomed at $14.1 million in Q3 2024.
  • The 5-year median for Shares Outstanding (Diluted Average) is $14.7 million (2022), against an average of $14.7 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) fell 4.38% in 2022 before it increased 8.27% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $14.9 million in 2021, then decreased by 2.29% to $14.6 million in 2022, then dropped by 0.29% to $14.5 million in 2023, then fell by 3.18% to $14.1 million in 2024, then rose by 5.65% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Shares Outstanding (Diluted Average) are $14.9 million (Q4 2025), $15.0 million (Q3 2025), and $15.3 million (Q2 2025).